Cargando…
Novel aspects of antiplatelet therapy in cardiovascular disease
Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y(12) receptor blockers. Gl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046593/ https://www.ncbi.nlm.nih.gov/pubmed/30046748 http://dx.doi.org/10.1002/rth2.12115 |
_version_ | 1783339845313101824 |
---|---|
author | Gremmel, Thomas Michelson, Alan D. Frelinger, Andrew L. Bhatt, Deepak L. |
author_facet | Gremmel, Thomas Michelson, Alan D. Frelinger, Andrew L. Bhatt, Deepak L. |
author_sort | Gremmel, Thomas |
collection | PubMed |
description | Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y(12) receptor blockers. Glycoprotein IIb‐IIIa antagonists are intravenously available antiplatelet agents preventing platelet‐to‐platelet aggregation via the fibrinogen receptor. The thrombin receptor inhibitor vorapaxar allows the targeting of yet a third pathway of platelet activation. Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease. Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual antiplatelet therapy, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents. |
format | Online Article Text |
id | pubmed-6046593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60465932018-07-25 Novel aspects of antiplatelet therapy in cardiovascular disease Gremmel, Thomas Michelson, Alan D. Frelinger, Andrew L. Bhatt, Deepak L. Res Pract Thromb Haemost Review Articles Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y(12) receptor blockers. Glycoprotein IIb‐IIIa antagonists are intravenously available antiplatelet agents preventing platelet‐to‐platelet aggregation via the fibrinogen receptor. The thrombin receptor inhibitor vorapaxar allows the targeting of yet a third pathway of platelet activation. Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease. Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual antiplatelet therapy, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents. John Wiley and Sons Inc. 2018-05-27 /pmc/articles/PMC6046593/ /pubmed/30046748 http://dx.doi.org/10.1002/rth2.12115 Text en © 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Gremmel, Thomas Michelson, Alan D. Frelinger, Andrew L. Bhatt, Deepak L. Novel aspects of antiplatelet therapy in cardiovascular disease |
title | Novel aspects of antiplatelet therapy in cardiovascular disease |
title_full | Novel aspects of antiplatelet therapy in cardiovascular disease |
title_fullStr | Novel aspects of antiplatelet therapy in cardiovascular disease |
title_full_unstemmed | Novel aspects of antiplatelet therapy in cardiovascular disease |
title_short | Novel aspects of antiplatelet therapy in cardiovascular disease |
title_sort | novel aspects of antiplatelet therapy in cardiovascular disease |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046593/ https://www.ncbi.nlm.nih.gov/pubmed/30046748 http://dx.doi.org/10.1002/rth2.12115 |
work_keys_str_mv | AT gremmelthomas novelaspectsofantiplatelettherapyincardiovasculardisease AT michelsonaland novelaspectsofantiplatelettherapyincardiovasculardisease AT frelingerandrewl novelaspectsofantiplatelettherapyincardiovasculardisease AT bhattdeepakl novelaspectsofantiplatelettherapyincardiovasculardisease |